Actuate Therapeutics closed a $17.25 million public offering, selling 2,464,286 shares for cancer treatment development.
Quiver AI Summary
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the closing of its underwritten public offering, raising $17.25 million by selling 2,464,286 shares of common stock at $7.00 per share. The offering includes 321,428 shares issued through an over-allotment option exercised by the underwriter. Actuate intends to use the net proceeds, approximately $15.62 million, for working capital and general corporate purposes. The offering was managed by Lucid Capital Markets, with Titan Partners Group serving as a financial advisor and legal representation provided by Greenberg Traurig, LLP and Lowenstein Sandler LLP. Actuate focuses on developing therapies for challenging cancers through the inhibition of GSK-3β, with its lead investigational drug, elraglusib, targeting tumor growth pathways and potentially enhancing anti-tumor immunity.
Potential Positives
- Actuate Therapeutics successfully closed a $17.25 million underwritten public offering, indicating strong investor interest and financial support for the company's growth.
- The offering included the full exercise of the underwriter's over-allotment option, reflecting confidence in the company's stock by both the underwriter and the market.
- Proceeds from the offering are intended for working capital and general corporate purposes, which will support the company's ongoing development of its cancer therapies.
- The press release highlights Actuate's focus on innovative treatments for high-impact, difficult-to-treat cancers, positioning the company within a critical and growing market sector.
Potential Negatives
- The company raised capital through a public offering, which may signal to investors that cash reserves are dwindling or that the company needs additional funding for ongoing operations or development projects.
- All shares sold in the offering were from the company itself, indicating that existing shareholders may face dilution of their ownership percentages.
- The press release emphasizes the use of proceeds for "working capital and general corporate purposes," which can be viewed as a lack of specific, growth-oriented projects, potentially raising concerns about the strategic direction of the company.
FAQ
What is Actuate Therapeutics focused on?
Actuate Therapeutics is dedicated to developing therapies for high-impact, difficult-to-treat cancers using GSK-3β inhibition.
How much did Actuate Therapeutics raise in its public offering?
Actuate Therapeutics raised $17.25 million through its underwritten public offering of common stock.
Who managed the public offering for Actuate Therapeutics?
Lucid Capital Markets acted as the sole book-running manager for Actuate Therapeutics' public offering.
What will the proceeds from the offering be used for?
The net proceeds of approximately $15.62 million will be used for working capital and general corporate purposes.
Where can I find the final prospectus supplement for the offering?
The final prospectus supplement is available on the SEC’s website at http://www.sec.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACTU Insider Trading Activity
$ACTU insiders have traded $ACTU stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ACTU stock by insiders over the last 6 months:
- AARON G.L. FLETCHER purchased 71,428 shares for an estimated $499,996
- LESLIE W. KREIS purchased 71,428 shares for an estimated $499,996
- EQUITY COF, LP BIOS purchased 71,428 shares for an estimated $499,996
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ACTU Analyst Ratings
Wall Street analysts have issued reports on $ACTU in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 08/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/17/2025
To track analyst ratings and price targets for $ACTU, check out Quiver Quantitative's $ACTU forecast page.
$ACTU Price Targets
Multiple analysts have issued price targets for $ACTU recently. We have seen 2 analysts offer price targets for $ACTU in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Mayank Mamtani from B. Riley Securities set a target price of $20.0 on 08/26/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $20.0 on 08/18/2025
Full Release
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price, before underwriting discounts and commissions, for each share of common stock was $7.00. All of the securities in the underwritten public offering were sold by the Company.
Lucid Capital Markets acted as sole book-running manager for the offering. Titan Partners Group, a division of American Capital Partners, acted as financial advisor in connection with the offering.
Greenberg Traurig, LLP represented the Company and Lowenstein Sandler LLP represented the underwriter in the transaction.
The Company intends to use the net proceeds from the offering of approximately $15.62 for working capital and general corporate purposes.
The common stock described above was offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333- 289988 ), including a base prospectus, previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov . Copies of the final prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from Lucid Capital Markets, LLC, 570 Lexington Avenue, 40 th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the intended use of proceeds from the offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed under the caption “Risk Factors” in the final prospectus supplement related to the offering. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
[email protected]
Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604
